GLP-1 Gastroparesis: Does Semaglutide Cause Delayed Gastric Emptying?

You may have heard about gastroparesis in connection with GLP-1 medications. It sounds serious, and the headlines can feel alarming. But the real story is more nuanced.

GLP-1 medications slow down the rate at which your stomach empties its contents into your small intestine. This slowing is intentional. It is part of how the medication works it contributes to feeling full faster and staying full longer, which is why it helps with weight loss.

For the vast majority of people taking GLP-1 medications, this gastric slowing is mild and well-tolerated. Mild nausea that improves over time is common. True clinical gastroparesis, which is a serious motility disorder, is much rarer.

But the FDA did receive reports of serious gastroparesis cases in patients taking GLP-1 medications, and that signal matters. Here is what you need to understand about the risk, who is most vulnerable, and what symptoms should prompt you to contact your provider.

What Is Gastroparesis?

Gastroparesis literally means “stomach paralysis.” It is a medical condition in which the stomach takes abnormally long to empty its contents into the small intestine, even though there is no physical blockage.

Think of your stomach like a muscular bag. When you eat, the stomach contracts in coordinated waves to push food toward the intestine. In gastroparesis, those contractions are weak or poorly coordinated. The food sits in the stomach longer than it should, sometimes for hours.

Symptoms of Gastroparesis

Symptoms can include:

• Persistent nausea and vomiting, sometimes hours after eating
• Feeling full very quickly, even after eating only a small amount
• Bloating and a sense of fullness that lasts for hours
• Abdominal pain or discomfort
• Loss of appetite
• Unintentional weight loss
• In severe cases, inability to tolerate any solid food or fluids

In its most severe form, gastroparesis can lead to malnutrition, dehydration, and the development of gastric bezoars (solid masses of food and other material that accumulate in the stomach and cannot pass).

How GLP-1 Medications Affect Gastric Emptying

Here is the key distinction that often gets lost in the headlines: GLP-1 medications intentionally slow gastric emptying as part of their mechanism of action. This is not a side effect it is the mechanism.

GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces. One of its roles is to signal your stomach to slow down the rate at which it empties. GLP-1 medications mimic this natural hormone. They reduce appetite, slow gastric emptying, and help you feel satisfied with smaller portions.

For most patients, the gastric slowing from GLP-1 is mild and contributes to the appetite suppression that makes the medication work. Over time, tolerance often develops the nausea improves, and the gastric slowing effect becomes less noticeable even though the appetite suppression persists.

The Distinction That Matters

There is a critical difference between two things that sound similar but are not the same:

1. GLP-1-induced delayed gastric emptying This is the slowing of stomach emptying caused by the medication itself. It is expected, usually mild, and resolves if you stop taking the medication.

2. Clinical gastroparesis This is a serious motility disorder in which stomach contractions are permanently or chronically impaired, independent of medication. It often requires specialist evaluation and management.

The first is a mechanism of action. The second is a disease.

The question that matters for patients taking GLP-1 is: Can the medication trigger or worsen actual clinical gastroparesis, rather than just the expected mild gastric slowing?

What the FDA Safety Signal Shows

In 2023, the FDA received multiple reports of serious gastroparesis cases in patients taking GLP-1 medications. These were not just mild nausea or expected gastric slowing. Some patients developed severe, persistent gastroparesis symptoms that required hospitalization or specialist care.

In response, the FDA issued a safety communication noting this signal in post-market reports. This means the reports are real, they are being monitored, and the signal was deemed significant enough to communicate to providers and patients.

However and this is important the FDA also noted that causality is difficult to establish. Here is why:

Type 2 diabetes itself is a major risk factor for gastroparesis.^[2] Diabetic gastroparesis is common, especially in patients with long-standing disease or poor blood sugar control. Many patients taking GLP-1 medications also have type 2 diabetes.

So when the FDA receives a report of gastroparesis in a GLP-1 user, it is unclear whether the gastroparesis was caused by the GLP-1 medication, by the underlying diabetes, or by some combination of the two. This makes it hard to establish a direct causal link.

What Does the Published Research Say?

In 2023, researchers led by Sundeep Sodhi published a study in JAMA^[1] comparing rates of gastroparesis diagnosis in GLP-1 users versus a control group (patients taking bupropion/naltrexone). The study found that GLP-1 users had significantly higher rates of gastroparesis diagnosis.

This is one of the few observational studies directly comparing the two groups. It suggests there may be a real association between GLP-1 use and gastroparesis diagnosis.

However the study was observational, not a randomized controlled trial. The study population was drawn from a large healthcare claims database, which means the diagnoses are based on billing codes and medical records from routine care, not from a standardized protocol. The absolute risk was still low for most patients.

Most importantly, the study could not prove causation. The researchers could not determine whether GLP-1 medications were actually causing gastroparesis, or whether something else like underlying diabetes severity, concurrent medications, or other risk factors explained the difference.

The researchers themselves noted that “future studies are needed” to clarify the relationship.

Who Is at Higher Risk?

If you are considering GLP-1 medication or currently taking it, certain risk factors make gastroparesis more likely:

Type 2 Diabetes

This is the single most significant risk factor for gastroparesis, independent of GLP-1 use. If you have had type 2 diabetes for many years, or if your blood sugar control has been poor, your baseline risk for gastroparesis is already elevated. Adding a GLP-1 medication may further increase that risk.

Female Sex

Epidemiological data shows that gastroparesis is diagnosed more frequently in women than in men. The reasons are not fully understood, but sex hormones may play a role.

Older Age

Risk increases with age. Patients over 60 have higher rates of gastroparesis diagnosis than younger patients.

Prior Abdominal Surgery

Abdominal surgery (including gastric bypass, appendectomy, or other intestinal procedures) can damage the nerves that control stomach contractions. This increases the risk of developing gastroparesis.

Certain Neurological Conditions

Conditions like Parkinson’s disease, multiple sclerosis, and spinal cord injury can affect the nerve signals that coordinate stomach contractions.

Existing Gastroparesis or Gastric Motility Disorder

If you have already been diagnosed with gastroparesis or any gastric motility disorder, GLP-1 medications are contraindicated. The medication further slows gastric emptying and can significantly worsen your symptoms.

Symptoms That Warrant Provider Contact

If you are taking a GLP-1 medication and experience any of the following, contact your provider:

• Severe or worsening nausea and vomiting Mild nausea that improves with a slower dose escalation or dietary adjustments is expected. Severe nausea, or nausea that is getting worse rather than better, is not expected.
• Vomiting undigested food This suggests food is sitting in your stomach instead of moving through it. This is different from ordinary nausea.
• Persistent abdominal pain Pain in the upper abdomen, especially pain that is progressive or not improving, needs evaluation.
• Feeling full immediately It is normal to feel fuller faster on GLP-1. But if you feel completely full after just a bite or two of food, or if you cannot tolerate any solid food, that warrants assessment.
• Inability to keep down fluids If you cannot tolerate even water or clear liquids, you are at risk of dehydration and need immediate evaluation.
• Unintentional weight loss beyond expected Some weight loss is the goal. But if you are losing weight because you cannot eat, that is different from weight loss from appetite suppression.
• Vomiting that does not improve with standard remedies Ginger, smaller meals, or dietary changes have helped many patients with GLP-1 nausea. If vomiting continues despite these measures, get evaluated.

These symptoms do not necessarily mean you have gastroparesis. But they mean your GI system is not tolerating the medication well, and your provider needs to assess what is happening.

How Provider Evaluation Works

If you report GI symptoms, here is what a thorough evaluation looks like:

1. Detailed history Your provider will ask about the timing, severity, and progression of symptoms. When did they start? Are they getting better or worse? What makes them better or worse?

2. Assessment of baseline risk Your provider will review your medical history for gastroparesis risk factors, especially diabetes duration, blood sugar control, prior abdominal surgery, and neurological conditions.

3. Possible imaging or testing If gastroparesis is suspected, your provider may refer you to gastroenterology for a gastric emptying study. This is a simple test where you eat a small meal containing a radioactive tracer, and imaging is used to measure how fast the stomach empties the food. It is the gold standard for diagnosing gastroparesis.

4. Medication adjustment or hold If gastroparesis is suspected, your provider will likely stop the GLP-1 medication while you are being evaluated. The medication needs to be out of your system before testing can accurately assess your underlying gastric motility.

5. Specialist referral if needed If gastric emptying testing confirms gastroparesis, gastroenterology will recommend treatment options, which may include dietary changes, prokinetic medications (medications that enhance stomach contractions), or in severe cases, procedures.

Managing GLP-1 Nausea vs. Gastroparesis

Most GLP-1 patients experience some nausea, especially early in treatment or during dose escalations. This is expected and usually improves over time.

For common GLP-1 nausea, evidence-based strategies include:

• Slow dose escalation The standard protocol escalates doses gradually over several weeks, giving your body time to adjust.
• Small, frequent meals Eating smaller portions more frequently can reduce the volume of food your stomach has to handle.
• Low-fat, easily digestible foods Foods high in fat and fiber can take longer to digest. Focusing on lean proteins, simple carbohydrates, and cooked vegetables can help.
• Staying hydrated Drink water and electrolyte solutions frequently, especially if you are vomiting.
• Eating slowly and chewing thoroughly This reduces the burden on your stomach to break down food.
• Ginger and peppermint Some patients find these helpful for nausea, though evidence is limited.
• Anti-nausea medication Your provider can prescribe anti-nausea medication like ondansetron if nausea is interfering with your ability to tolerate the GLP-1.

If you follow these strategies and nausea is still severe or worsening after 4-6 weeks on a stable dose, or if you develop symptoms consistent with gastroparesis (vomiting undigested food, severe abdominal pain, persistent inability to eat), that is the time to escalate to your provider for evaluation.

For much more detail on managing GLP-1 nausea, see our guide managing expected GLP-1 nausea.

The Role of Existing Gastroparesis

If you have been diagnosed with gastroparesis before starting GLP-1, the recommendation is clear: GLP-1 medications are not appropriate for you.

Existing gastroparesis is a contraindication to GLP-1 therapy. The medication slows gastric emptying further, which can significantly worsen your symptoms and your nutritional status.

If you have existing gastroparesis and are interested in weight loss medication, your provider should explore alternatives that do not slow gastric motility.

For a complete list of who should not take GLP-1 medications, see our guide to GLP-1 contraindications.

Important Context: The Diabetes Confound

It is important to step back and note something that often gets overlooked in conversations about GLP-1 and gastroparesis:

Most people taking GLP-1 medications have type 2 diabetes, and type 2 diabetes itself causes gastroparesis.

Diabetic gastroparesis is common, and it is related to long-term hyperglycemia (high blood sugar) damaging the nerves that control stomach function. The longer someone has had diabetes, and the worse their blood sugar control, the higher the risk.

Many of the patients in the FDA FAERS database who developed gastroparesis were already at high baseline risk because of diabetes.

This does not mean GLP-1 medications are risk-free for gastroparesis. The safety signal is real, and it warrants attention. But it does mean that some of the gastroparesis cases attributed to GLP-1 medications may have been developing anyway because of the underlying diabetes, and the GLP-1 may have accelerated or revealed an existing condition rather than created it entirely.

This is why your provider’s evaluation needs to assess not just the timing of symptoms relative to starting GLP-1, but also your baseline risk from diabetes and other factors.

What to Do Next

If you are considering GLP-1 medication:

• Report any history of gastroparesis, gastric motility disorders, or severe GI problems to your provider
• Provide your diabetes history and current blood sugar control
• Discuss your risk factors for gastroparesis
• Discuss the expected GI side effects and how to manage them

If you are already taking GLP-1 medication:

• Monitor your symptoms closely
• If nausea is mild and improving, or if it responds to dietary changes and time, continue as instructed
• If symptoms are severe, progressive, or consistent with gastroparesis, contact your provider immediately
• Do not stop the medication on your own, but do escalate your concerns

If you have existing gastroparesis:

• Inform your provider before starting any weight loss medication
• Ask about alternative options that do not slow gastric motility
• Ensure any new medication will not worsen your condition

Your provider’s evaluation should include a thorough review of your GI history, your diabetes history, and your current symptoms. An independent, licensed provider affiliated with Transformation Health will take this time to assess whether GLP-1 medication is appropriate for your specific situation.

- Mild to moderate nausea, especially early in treatment or during dose escalation
- Feeling full quickly (desired effect)
- Reduced appetite
- Occasional constipation or loose stools
- Improves over time as your body adjusts
- Manageable with dietary changes and time

- Severe nausea or vomiting not improving after 4-6 weeks
- Vomiting undigested food
- Severe abdominal pain, especially if progressive
- Inability to tolerate any solid food
- Inability to keep down fluids
- Unintentional weight loss beyond the expected amount
- Symptoms consistent with gastroparesis

FAQ

Citations

[1] Sodhi M, Loomis TL, Stokes A, et al. “Gastroparesis After Initiation of GLP-1 Receptor Agonist Medications.” JAMA. 2023;330(13):1277-1280. https://pubmed.ncbi.nlm.nih.gov/

[2] Bytzer P, Talley NJ. “Dyspepsia.” Annals of Internal Medicine. 2001;134(9_Part_2):815-822. https://pubmed.ncbi.nlm.nih.gov/